AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Welcome Scientific update to Pune, India 2-3 and 4-5 Dec 2014 for celebrating Process chemistry

 companies, PROCESS  Comments Off on Welcome Scientific update to Pune, India 2-3 and 4-5 Dec 2014 for celebrating Process chemistry
Sep 292014
 

 

WEBSITE http://www.scientificupdate.co.uk/

SCIENTIFIC UPDATE HAS A REPUTATION FOR ITS HIGH QUALITY EVENTS, BOTH FOR THE SCIENTIFIC CONTENT AND ALSO FOR THE EFFICIENCY OF ITS ORGANISATION. KEEP YOUR SKILLS UP TO DATE AND INVEST IN YOUR CONTINUING PERSONAL PROFESSIONAL DEVELOPMENT.

http://makeinindia.com/

TRAINING COURSE   2-3 DEC 2014

Process Development for Low Cost Manufacturing

When:02.12.2014 – 03.12.2014

Tutors:

Where: National Chemical Laboratory – Pune, India

Brochure:View Brochure

Register http://scientificupdate.co.uk/training/scheduled-training-courses.html

 

DESCRIPTION

Chemical process research and development is recognised as a key function during the commercialisation of a new product particularly in the generic and contract manufacturing arms of the chemical, agrochemical and pharmaceutical industries.

The synthesis and individual processes must be economic, safe and must generate product that meets the necessary quality requirements.

This 2-day course presented by highly experienced process chemists will concentrate on the development and optimisation of efficient processes to target molecules with an emphasis on raw material cost, solvent choice, yield improvement, process efficiency and work up, and waste minimisation.

Process robustness testing and reaction optimisation via stastical methods will also be covered.

A discussion of patent issues and areas where engineering and technology can help reduce operating costs.

The use of engineering and technology solutions to reduce costs will be discussed and throughout the course the emphasis will be on minimising costs and maximising returns.

 

 

Conference 4-5 DEC 2014

TITLE . Organic Process Research & Development – India

Subtitle:The 32nd International Conference and Exhibition

When:04.12.2014 – 05.12.2014

Where:National Chemical Laboratory – Pune, India

Brochure:View Brochure

Register..http://scientificupdate.co.uk/conferences/conferences-and-workshops.html

Organic Process Research & Development - India

for

  • Process Research & Development Chemists
  • Chemical Engineers in Industry
  • Heads of Departments & Team Leaders

Benefits

  • Invest in yourself: keeping up to date on current developments and future trends could mean greater job security.
  • Learn from a wide range of industrial case studies given by hand-picked industrial speakers.
  • Take home relevant ideas and information that are directly applicable to your own work with the full proceedings and a CD of the talks.
  • Save time. Our intensive, commercial-free programme means less time away from work.
  • Meet and network with the key people in the industry in a relaxed and informal atmosphere.

Do you want to improve efficiency and innovation in your synthetic route design, development and optimisation?

The efficient conversion of a chemical process into a process for manufacture on tonnage scale has always been of importance in the chemical and pharmaceutical industries. However, in the current economic and regulatory climate, it has become increasingly vital and challenging to do so efficiently. Indeed, it has never been so important to keep up to date with the latest developments in this dynamic field.

At this Organic Process Research & Development Conference, you will hear detailed presentations and case studies from top international chemists. The hand-picked programme of speakers has been put together specifically for an industrial audience. They will discuss the latest issues relating to synthetic route design, development and optimisation in the pharmaceutical, fine chemical and allied fields.  Unlike other conferences, practically all our speakers are experts from industry, which means the ideas and information you take home will be directly applicable to your own work.

The smaller numbers at our conferences create a more intimate atmosphere. You will enjoy plenty of opportunities to meet and network with speakers and fellow attendees during the reception, sit-down lunches and extended coffee breaks in a relaxed and informal environment. Together, you can explore the different strategies and tactics evolving to meet today’s challenges.

This is held in Pune, close proximity to Mumbai city, very convenient to stay and travel to either in Pune or Mumbai. I feel this should be an opportunity to be grabbed before the conference is full and having no room

Hurry up rush

References

http://newdrugapprovals.org/scientificupdate-uk-on-a-roll/

http://scientificupdate.co.uk/conferences/conferences-and-workshops.html

http://en.wikipedia.org/wiki/Pune

PROFILES

Will Watson

Will Watson

Dr Will Watson gained his PhD in Organic Chemistry from the University of Leeds in 1980. He joined the BP Research Centre at Sunbury-on-Thames and spent five and a half years working as a research chemist on a variety of topics including catalytic dewaxing, residue upgrading, synthesis of novel oxygenates for use as gasoline supplements, surfactants for use as gasoline detergent additives and non-linear optical compounds.

In 1986 he joined Lancaster Synthesis and during the next 7 years he was responsible for laboratory scale production and process research and development to support Lancaster’s catalogue, semi-bulk and custom synthesis businesses.

In 1993 he was appointed to the position of Technical Director, responsible for all Production (Laboratory and Pilot Plant scale), Process Research and Development, Engineering and Quality Control. He helped set up and run the Lancaster Laboratories near Chennai, India and had technical responsibility for the former PCR laboratories at Gainesville, Florida.

He joined Scientific Update as Technical Director in May 2000. He has revised and rewritten the ‘Chemical Development and Scale Up in the Fine Chemical & Pharmaceutical Industries’ course and gives this course regularly around the world. He has been instrumental in setting up and developing new courses such as ‘Interfacing Chemistry with Patents’ and ‘Making and Using Fluoroorganic Molecules’.

He is also involved in an advisory capacity in setting up conferences and in the running of the events. He is active in the consultancy side of the business and sits on the Scientific Advisory Boards of various companies.

………………………………………………………………………………………………….

John Knight

John Knight

Dr John Knight gained a first class honours degree in chemistry at the University of Southampton, UK. John remained at Southampton to study for his PhD in synthetic methodology utilizing radical cyclisation and dipolar cyloaddition chemistry.

After gaining his PhD, John moved to Columbia University, New York, USA where he worked as a NATO Postdoctoral Fellow with Professor Gilbert Stork. John returned to the UK in 1987 joining Glaxo Group Research (now GSK) as a medicinal chemist, where he remained for 4 years before moving to the process research and development department at Glaxo, where he remained for a further 3½ years.

During his time at Glaxo, John worked on a number of projects and gained considerable plant experience (pilot and manufacturing). In 1994 John moved to Oxford Asymmetry (later changing its name to Evotec and most recently to Aptuit) when it had just 25 staff. John’s major role when first at Oxford Asymmetry was to work with a consultant project manager to design, build and commission a small pilot plant, whilst in parallel developing the chemistry PRD effort at Oxford Asymmetry.

The plant was fully operational within 18 months, operating to a 24h/7d shift pattern. John continued to run the pilot plant for a further 3 years, during which time he had considerable input into the design of a second plant, which was completed and commissioned in 2000. After an 18-month period at a small pharmaceutical company, John returned to Oxford in 2000 (by now called Evotec) to head the PRD department. John remained in this position for 6.5 years, during which time he assisted in its expansion, established a team to perform polymorph and salt screening studies and established and maintained high standards of development expertise across the department.

John has managed the chemical development and transfer of numerous NCE’s into the plant for clients and been involved in process validations. He joined Scientific Update in January 2008 as Scientific Director.

Pune images

From top: Fergusson College, Mahatma Gandhi Road (left), Shaniwarwada (right), the HSBC Global Technology India Headquarters, and the National War Memorial Southern Command
From top:1 Fergusson College, 2 Mahatma Gandhi RoadShaniwarwada 3 the HSBC Global Technology India Headquarters, and the 4National War Memorial Southern Command

 

NCL PUNE

The National Chemical Laboratory is located in the state of Maharashtra in India. Maharashtra state is the largest contributor to India’s GDP. The National Chemical Laboratory is located in Pune city, and is the cultural capital of Maharashtra. Pune city is second only to Mumbai (the business capital of India) in size and industrial strength. Pune points of interest include: The tourist places in Pune include: Lal Deval Synagogue, Bund Garden, Osho Ashram, Shindyanchi Chhatri and Pataleshwar Cave Temple.

http://makeinindia.com/

MAKE IN INDIA

http://makeinindia.com/

http://makeinindia.com/sector/pharmaceuticals/

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

 

 

 

KEYWORDS

JOHN KNIGHT, WILL WATSON,  SCIENTIFIC UPDATE, PROCESS, COURSE, CONFERENCE, INDIA, PUNE, PROCESS DEVELOPMENT, LOW COST,  MANUFACTURING, SCALEUP

Share

Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors

 cancer  Comments Off on Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors
Sep 262014
 

Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors

R.M. Myers,* J.W. Shearman, M.O. Kitching, A. Ramos-Montoya, D.E. Neal, S.V. Ley, ACS Chem. Biol.2009, 4, 503-525.

see

http://pubs.acs.org/doi/abs/10.1021/cb900038e

The literature covering neurotensin (NT) and its signalling pathways, receptors, and biological profile is complicated by the fact that the discovery of three NT receptor subtypes has come to light only in recent years. Moreover, a lot of this literature explores NT in the context of the central nervous system and behavioral studies. However, there is now good evidence that the up-regulation of NT is intimately involved in cancer development and progression. This Review aims to summarize the isolation, cloning, localization, and binding properties of the accepted receptor subtypes (NTR1, NTR2, and NTR3) and the molecules known to bind at these receptors. The growing role these targets are playing in cancer research is also discussed. We hope this Review will provide a useful overview and a one-stop resource for new researchers engaged in this field at the chemistry−biology interface.

Keywords:

Agonist: A molecule that binds to a specific receptor and triggers a response in the cell mimicking the action of an endogenous ligand.Antagonist: A molecule that binds to a specific receptor yet does not provoke a biological response itself upon binding but blocks or dampens the agonist-mediated response.Homology and identity: Measures of similarity between protein sequences. Homology implies an evolutionary link and is qualitative, whereas identity is quantifiable.Site-directed mutagenesis: A process where specific single nucleotide changes within a gene can be made resulting in the change of a specific amino acid within a protein sequence.Prognostic factor: A biomarker that can be used to estimate the chance of recovery from a disease or the chance of the disease recurring.Predictive factor: A biomarker used to predict the response of a cancer to a given therapy.

Share

I did not run away from a NaCN Exotherm

 PROCESS  Comments Off on I did not run away from a NaCN Exotherm
Sep 242014
 

 

Deltamethrin

DELTAMETHRIN

DID NOT RUN AWAY FROM NACN ie sodium cyanide EXOTHERM

ALMOST VIRTUAL ACCIDENT AT RPG LIFESCIENCES (SEARLE) PANOLI GUJARAT INDIA 1999-2000 

DELTAMETHRIN PROJECT, 1999-2000 Panoli Gujarat India

I Was trying to add acid chloride into an aldehyde at zero degrees cent using PTC conditions and one of ingredient was sodium cyanide, cooling was done by brine

I Did not run away when instead of adding acid chloride in 2 hrs the operator added it on 10 min…………..I waited at the reactor and controlled an exotherm in plant by switching off brine supply to other reactors,

The reaction got controlled at 59 deg cent and luckily was ok…………the exotherm was fearful.

 

Despite all odds God saves us

 

 

http://makeinindia.com/ MAKE IN INDIA
http://makeinindia.com/
http://makeinindia.com/sector/pharmaceuticals/

 

Share

A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies

 MONOCLONAL ANTIBODIES  Comments Off on A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies
Sep 232014
 

image

 

A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies

CLICK…….http://www.sciencedirect.com/science/article/pii/S0960894X1400866X

Volume 24, Issue 19, 1 October 2014, Pages 4664–4666

DOI: 10.1016/j.bmcl.2014.08.035
Lisa M. Eubanks, Beverly A. Ellis, Xiaoqing Cai, Joel E. Schlosburg, Kim D. Janda

Abstract

Cocaine abuse remains prevalent worldwide and continues to be a major health concern; nonetheless, there is no effective therapy. Immunopharmacotherapy has emerged as a promising treatment strategy by which anti-cocaine antibodies bind to the drug blunting its effects. Previous passive immunization studies using our human monoclonal antibody, GNCgzk, resulted in protection against cocaine overdose and acute toxicity. To further realize the clinical potential of this antibody, a recombinant IgG form of the antibody has been produced in mammalian cells. This antibody displayed a high binding affinity for cocaine (low nanomolar) in line with the superior attributes of the GNCgzk antibody and reduced cocaine-induced ataxia in a cocaine overdose model.

 

 

Keywords

  • Cocaine;
  • Overdose;
  • Immunopharmacotherapy;
  • Passive immunization;
  • Monoclonal antibody
Share

A smarter way to find new drugs

 companies  Comments Off on A smarter way to find new drugs
Sep 232014
 

 

 

End to end solutions Big Data push to research In Green / shutterstock.com
End to end solutions Big Data push to research In Green / shutterstock.com

The pharma sector needs to embrace emerging technologies like Big Data analytics and cloud computing

What is the secret sauce of accelerating innovation when it comes to critical areas such as drug discovery, personalised medicines or simulated healthcare? Embracing continual innovation was always an imperative for the life sciences companies to stay relevant, and stay alive. This is not just confined to the new drug discovery team within the company, it spans the entire value chain of the innovation ecosystem. The question is whether enough is being done to drive R&D innovation in the pharmaceutical industry.

read all at

http://m.thehindubusinessline.com/opinion/a-smarter-way-to-find-new-drugs/article6435802.ece/

 

 

 

 

Share

Continuous flow chemistry: a discovery tool for new chemical reactivity patterns

 SYNTHESIS  Comments Off on Continuous flow chemistry: a discovery tool for new chemical reactivity patterns
Sep 212014
 

 

GA-1

 

 

Continuous flow chemistry: a discovery tool for new chemical reactivity patterns

Jan Hartwig,a   Jan B. Metternich,b   Nikzad Nikbin,b  Andreas Kirschninga and   Steven V. Ley*b  

*Corresponding authors
aInstitut für Organische Chemie, Leibniz Universität Hannover, Schneiderberg 1B, 30167 Hannover, Germany
bInnovative Technology Centre, Department of Chemistry, University of Cambridge, Lensfield Road, UK
Org. Biomol. Chem., 2014,12, 3611-3615

DOI: 10.1039/C4OB00662C

Continuous flow chemistry as a process intensification tool is well known. However, its ability to enable chemists to perform reactions which are not possible in batch is less well studied or understood. Here we present an example, where a new reactivity pattern and extended reaction scope has been achieved by transferring a reaction from batch mode to flow. This new reactivity can be explained by suppressing back mixing and precise control of temperature in a flow reactor set up.

 

Share
Sep 162014
 

 

 

An automated flow-based synthesis of imatinib: the API of gleevec 

M.D. Hopkin, I.R. Baxendale, S.V. Ley, J.C.S. Chem. Commun.2010, 46, 2450-2452.

http://pubs.rsc.org/en/Content/ArticleLanding/2010/CC/c001550d#!divAbstract

A concise, flow-based synthesis of Imatinib, a compound used for the treatment of chronic myeloid leukaemia, is described whereby all steps are conducted in tubular flow coils or cartridges packed with reagents or scavengers to effect clean product formation.

An in-linesolvent switching procedure was developed enabling the procedure to be performed with limited manual handling of intermediates.

Graphical abstract: A flow-based synthesis of Imatinib: the API of Gleevec

 

see supp info

http://www.rsc.org/suppdata/cc/c0/c001550d/c001550d.pdf

 

Share

Bitter Fruit Bears Protein That Can Act Like Insulin

 diabetes  Comments Off on Bitter Fruit Bears Protein That Can Act Like Insulin
Sep 152014
 
20140911lnp2-Figure2

INSULIN LITE
Researchers identified a protein (sphere representation) that binds to and activates the insulin receptor (ribbon structure), though it’s less potent at turning on the receptor than insulin itself.
Credit: J. Agric. Food Chem

Bitter Fruit Bears Protein That Can Act Like Insulin

Diabetes: Researchers discover a protein in bitter melon that binds to and activates the insulin receptor, offering a potential path to new diabetes treatments
Practitioners of traditional medicine have long turned to a knobby green fruit known as bitter melon (Momordica charantia) to treat ailments such as diabetes. Researchers dug into the melon and discovered a protein that binds to and activates the insulin receptor, improving glucose metabolism in diabetic mice (J. Agric. Food Chem. 2014, DOI: 10.1021/jf5002099). The protein may be a starting point for the development of novel therapies for diabetes, the scientists say.
read
20140911lnp2-bittermelon

THERAPEUTIC FRUIT?
Share

The flow synthesis of heterocycles for natural products and medicinal chemistry applications

 PROCESS, SYNTHESIS  Comments Off on The flow synthesis of heterocycles for natural products and medicinal chemistry applications
Sep 142014
 

The flow synthesis of heterocycles for natural products and medicinal chemistry applications

http://link.springer.com/article/10.1007%2Fs11030-010-9282-1

M. Baumann, I.R. Baxendale, S.V. Ley, Mol. Div. 2011, 15, 613-630.

This article represents an overview of recent research from the Innovative Technology Centre in the field of flow chemistry which was presented at the FROST2 meeting in Budapest in October 2009. After a short introduction of this rapidly expanding field, we discuss some of our results with a main focus on the synthesis of heterocyclic compounds which we use in various natural product and medicinal chemistry programmes.

Share

Synthesis of (-)-hennoxazole A: integrating batch and flow chemistry methods

 SYNTHESIS  Comments Off on Synthesis of (-)-hennoxazole A: integrating batch and flow chemistry methods
Sep 142014
 

 

Untitled-1

 

Synthesis of (-)-hennoxazole A: integrating batch and flow chemistry methods

A. Fernández, Z.G. Levine, M. Baumann, S. Sulzer-Mossé, C. Sparr, S. Schläger, A. Metzger, I.R. Baxendale, S.V. Ley,Synlett, 2013, 24, 514-518.

A new total synthesis of (–)-hennoxazole A is reported. The synthetic approach is based on the preparation of three similarly sized fragments resulting in a fast and convergent assembly of the natural product. The three key reactions of the synthesis include a highly stereoselective 1,5-anti aldol coupling, a gold-catalyzed alkoxycyclization reaction, and a stereocontrolled diene cross-meta­thesis. The synthesis involves integrated batch and flow chemistry methods leading to the natural product in 16 steps longest linear ­sequence and 2.8% overall yield.

read

https://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1318109

 

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: